Moteur de recherche d’entreprises européennes
Financement de l’UE (11,4 M €) : Une modalité de dépistage innovante, sans contact et inoffensive qui va changer le cours de la détection du cancer du sein et du suivi des patientes Hor02/12/2022 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Une modalité de dépistage innovante, sans contact et inoffensive qui va changer le cours de la détection du cancer du sein et du suivi des patientes
Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2.26 million new cases of breast cancer. Early detection is crucial to survival; recovery rates approach 90% when detected in early stages. National population-based cancer screening programmes in Europe currently implement 3 standard imaging modalities: mammography, ultrasound and MRI. The downsides of these screening methods include ionising radiation, high costs and high false positive rates in screening results. Our multidisciplinary consortium of 16 partners from 10 countries aims to contribute to EU’s Mission on Cancer and Beating Cancer Plan by drastically improving the prevention, diagnosis and monitoring of breast cancer while reducing the burden on women and female patients and their families, health care professionals and others who are directly or indirectly affected by breast cancer. ThermoBreast proposes a new solution for accurate, harmless and non-contact screening, equally applicable for all age groups and breast densities and capable of detecting pre-cancerous states. This risk-free screening technology, recently patented by the project coordinator ThermoMind LTD, can detect vascular anomalies and asymmetry, caused by cancerous growth. It combines innovative screening through multiple sensitive infrared sensors with advanced AI analysis of temporal dynamic thermal patterns. Through its patient-centred integrated diagnostics approach, this project converges intelligent computer vision, blood vessel extraction and tissue analysis with advanced information technology to deliver a medical class 1 device that will be validated in an international multicentre clinical study. To enhance stakeholder participation, ThermoBreast involves end users, SSH experts and a patient organisation in the co-creation of the new screening solution and assesses its health and socio-economic benefits as well as its cost effectiveness. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.
| ACCELOPMENT SCHWEIZ AG | ? |
| ACADEMISCH ZIEKENHUIS GRONINGEN | 491 875 € |
| ASSUTA MEDICAL CENTERS Ltd. | 531 987 € |
| Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino | 411 875 € |
| Cancer Patients Europe | 243 750 € |
| CYBER ONE GmbH | 1 187 500 € |
| Institut Gustave Roussy | 571 367 € |
| LIETUVOS SVEIKATOS MOKSLU UNIVERSITETO LIGONINE KAUNO KLINIKOS | 317 500 € |
| MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER | 197 500 € |
| TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY | 663 075 € |
| TECHNISCHE UNIVERSITAET MUENCHEN | 607 725 € |
| THERMOMIND Ltd. | 3 643 125 € |
| UNIVERSITATSKLINIKUM HEIDELBERG | 1 167 389 € |
| University College Cork - National University of Ireland, Cork | 691 938 € |
| Univerzitetni klinicni center Maribor | 297 875 € |
| Vrije Universiteit Brussel | 407 563 € |
https://cordis.europa.eu/project/id/101096329
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : accelopment Schweiz AG, Zurich, Suisse.